Martine Rothblatt, United Therapeutics CEO (Jack Plunkett/AP Images)

Unit­ed Ther­a­peu­tics tran­si­tions to pub­lic ben­e­fit cor­po­ra­tion more than 20+ years af­ter IPO

Unit­ed Ther­a­peu­tics has been a pub­lic com­pa­ny since 1999, but late Thurs­day the com­pa­ny an­nounced it’s en­ter­ing a new phase.

Unit­ed will be­come a pub­lic ben­e­fit cor­po­ra­tion in what the com­pa­ny claims is the first con­ver­sion of a pub­lic biotech or phar­ma­ceu­ti­cal com­pa­ny to PBC, Unit­ed said. The biotech not­ed it has pre­vi­ous ex­pe­ri­ence in the PBC world, hav­ing run a sub­sidiary as a pub­lic ben­e­fit cor­po­ra­tion for the past six years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.